Literature DB >> 28823367

Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.

Feng Shen1, Rui-Dan Zheng2, Xing-Qiang Sun3, Wen-Jin Ding1, Xiao-Ying Wang4, Jian-Gao Fan5.   

Abstract

BACKGROUND: Gut microbiota plays a significant role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). This study aimed to assess the contribution of gut microbiota dysbiosis to the pathogenesis of NAFLD.
METHODS: Forty-seven human feces samples (25 NAFLD patients and 22 healthy subjects) were collected and 16S rDNA amplicon sequencing was conducted on Hiseq 2000 platform. Discrepancy of species composition between controls and NAFLD group was defined by Metastats analysis under P value <0.01.
RESULTS: NAFLD patients harbored lower gut microbiota diversity than healthy subjects did. In comparison to the control group, the Proteobacteria (13.50%) and Fusobacteria (2.76%) phyla were more abundant in NAFLD patients. Additionally, the Lachnospiraceae (21.90%), Enterobacteriaceae (12.02%), Erysipelotrichaceae (3.83%), and Streptococcaceae (1.39%) families, as well as the Escherichia_Shigella (10.84%), Lachnospiraceae_Incertae_Sedis (7.79%), and Blautia (4.95%) genera were enriched in the NAFLD group. However, there was a lower abundance of Prevotella in the NAFLD group than that in the control group (5.83% vs 27.56%, P<0.01). The phylum Bacteroidetes (44.63%) also tended to be more abundant in healthy subjects, and the families Prevotellaceae (28.66%) and Ruminococcaceae (26.44%) followed the same trend. Compared to those without non-alcoholic steatohepatitis (NASH), patients with NASH had higher abundance of genus Blautia (5.82% vs 2.25%; P=0.01) and the corresponding Lachnospiraceae family (24.33% vs 14.21%; P<0.01). Patients with significant fibrosis had a higher abundance of genus Escherichia_Shigella (12.53% vs 1.97%; P<0.01) and the corresponding Enterobacteriaceae family (13.92% vs 2.07%; P<0.01) compared to those with F0/F1 fibrosis.
CONCLUSIONS: NAFLD patients and healthy subjects harbor varying gut microbiota. In contrast to the results of previous research on children, decreased levels of Prevotella might be detrimental for adults with NAFLD. The increased level of the genus Blautia, the family Lachnospiraceae, the genus Escherichia_Shigella, and the family Enterobacteriaceae may be a primary contributor to NAFLD progression.
Copyright © 2017 The Editorial Board of Hepatobiliary & Pancreatic Diseases International. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  fatty liver disease; fibrosis; gut microbiota; non-alcoholic steatohepatitis

Mesh:

Substances:

Year:  2017        PMID: 28823367     DOI: 10.1016/S1499-3872(17)60019-5

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  107 in total

Review 1.  Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.

Authors:  John Y L Chiang; Jessica M Ferrell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-27       Impact factor: 4.052

2.  Actively implementing enteral nutrition to reduce parenteral nutrition-associated liver disease.

Authors:  Shuifang Jin; Ronglin Jiang; Weibin Ma
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

Review 3.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Authors:  Suzanne R Sharpton; Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

4.  An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment.

Authors:  Marialena Mouzaki; Rohit Loomba
Journal:  Curr Treat Options Gastroenterol       Date:  2020-05-02

5.  Hydrogen sulfide and nonalcoholic fatty liver disease.

Authors:  Panzhi Wang; Liming Wu
Journal:  Hepatobiliary Surg Nutr       Date:  2018-04       Impact factor: 7.293

6.  Liver tumorigenesis is promoted by a high saturated fat diet specifically in male mice and is associated with hepatic expression of the proto-oncogene Agap2 and enrichment of the intestinal microbiome with Coprococcus.

Authors:  Kim B Pedersen; Casey F Pulliam; Aarshvi Patel; Fabio Del Piero; Tatiane T N Watanabe; Umesh D Wankhade; Kartik Shankar; Chindo Hicks; Martin J Ronis
Journal:  Carcinogenesis       Date:  2019-04-29       Impact factor: 4.944

7.  Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study.

Authors:  Chikara Iino; Tetsu Endo; Kenichiro Mikami; Takuma Hasegawa; Masayo Kimura; Naoya Sawada; Shigeyuki Nakaji; Shinsaku Fukuda
Journal:  Hepatol Int       Date:  2019-09-12       Impact factor: 6.047

Review 8.  Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?

Authors:  Tien S Dong; Jonathan P Jacobs
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-14

Review 9.  Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

Review 10.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.